Alector Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Alector wird ein jährliches Gewinn- und Umsatzwachstum von 12.4% bzw. 31.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 22.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -68.8% betragen.

Wichtige Informationen

12.4%

Wachstumsrate der Gewinne

22.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	31.3%
Zukünftige Eigenkapitalrendite	-68.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	12 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01

Recent updates

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Sep 25

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Jun 27

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Mar 02

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Jan 16

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Oct 04

AbbVie ends partnership with Alector for Alzheimer’s candidate

Jul 08

Alector: Potential In Neurology And Cancer Treatments

Jun 14

Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

May 18

Alector: Expect Phase 3 Data Next Year

Apr 16

These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts

Feb 27

Alector, Inc: A Newer Biotech Company With Big Potential

Jan 26

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ALEC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	107	-192	-213	-152	5
12/31/2025	128	-113	-134	-33	9
12/31/2024	63	-179	-158	-206	10
9/30/2024	62	-158	-222	-221	N/A
6/30/2024	55	-161	-218	-217	N/A
3/31/2024	96	-121	-199	-197	N/A
12/31/2023	97	-130	-187	-184	N/A
9/30/2023	96	-141	-190	-187	N/A
6/30/2023	102	-143	-194	-190	N/A
3/31/2023	126	-135	-208	-204	N/A
12/31/2022	134	-133	-24	-20	N/A
9/30/2022	133	-136	-25	-21	N/A
6/30/2022	301	36	471	473	N/A
3/31/2022	227	-29	483	486	N/A
12/31/2021	207	-36	295	299	N/A
9/30/2021	198	-33	297	300	N/A
6/30/2021	21	-212	-189	-186	N/A
3/31/2021	18	-202	-190	-187	N/A
12/31/2020	21	-190	-172	-167	N/A
9/30/2020	22	-169	-154	-148	N/A
6/30/2020	19	-148	-144	-136	N/A
3/31/2020	23	-127	-125	-108	N/A
12/31/2019	21	-105	-115	-99	N/A
9/30/2019	24	-92	-102	-88	N/A
6/30/2019	28	-76	-94	-82	N/A
3/31/2019	28	-62	-84	-81	N/A
12/31/2018	28	-52	126	127	N/A
9/30/2018	22	-45	141	143	N/A
6/30/2018	15	-39	N/A	159	N/A
3/31/2018	8	-35	N/A	171	N/A
12/31/2017	4	-32	N/A	-18	N/A
12/31/2016	0	-15	N/A	-13	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ALEC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ALEC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ALEC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ALECDie Einnahmen des Unternehmens (31.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: ALECDie Einnahmen des Unternehmens (31.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ALEC wird voraussichtlich in 3 Jahren unrentabel sein.

Alector Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024

Consensus revenue estimates decrease by 37%, EPS upgraded

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Recent updates

Alector, Inc. announced that it expects to receive $50 million in funding from Hercules Capital, Inc., and other investors

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

Alector, Inc. Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Co-Founder recently sold US$129k worth of stock

Co-Founder recently sold US$129k worth of stock

Board Member recently sold US$228k worth of stock

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Co-Founder recently sold US$121k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024

First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.55 loss in 1Q 2023)

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold US$130k worth of stock

Consensus revenue estimates decrease by 37%, EPS upgraded

Co-Founder notifies of intention to sell stock

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million.

New minor risk - Shareholder dilution

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Alector: Good Data, Huge Cash, No Near Term Catalyst

Insufficient new directors

New major risk - Revenue and earnings growth

Co-Founder recently sold US$133k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)

Price target decreased by 12% to US$15.40

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Alector, Inc. Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002

Consensus revenue estimates increase by 244%

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Price target decreased by 13% to US$14.33

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. Provides Revenue Guidance for the Year 2023

Co-Founder recently sold US$94k worth of stock

Consensus revenue estimates decrease by 24%

Consensus revenue estimates fall by 79%

Key Executive recently sold US$84k worth of stock

Price target decreased by 20% to US$16.94

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Full year 2022 earnings released: US$1.62 loss per share (vs US$0.45 loss in FY 2021)

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$21.44

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Alector, Inc. Announces Promotion of Clare Hunt to Chief People Officer

Alector, Inc. Announces Resignation of Robert King as Chief Development Officer

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Alector, Inc. Initiates Phase 1 Clinical Trial of Al044 for the Treatment of Alzheimer’s Disease

Consensus revenue estimates increase by 13%

Price target decreased to US$24.96